Wolters Kluwer agrees to buy AgileMD for up to $100 million

what happened

Wolters Kluwer has agreed to acquire AgileMD, a developer of an AI-powered clinical decision support platform, for up to $100 million. Of that amount, $40 million will be paid upfront, while the rest depends on meeting specified performance targets. According to TradingView, citing GlobeNewswire, AgileMD's annual recurring revenue is expected to reach $7 million by the end of 2026.

The company expects the deal to have an immaterial near-term effect on adjusted earnings and to earn returns at or above its 8% weighted average cost of capital within three to five years. Closing is expected in Q1 2027 or sooner, subject to customary conditions and government approvals.

why it matters

For investors this is a small deal: AgileMD is modest in scale relative to Wolters Kluwer, and the company says the earnings effect will be minimal. It is a step in expanding its health decision-support business, but it is unlikely to move the stock materially.

market impact

Wolters Kluwer: small deal in health decision support, earnings effect expected to be minimal

tags

instruments